Kalkine has a fully transformed New Avatar.

small-cap

One Health Care Equipment & Services Stock Trading Near Resistance Levels – IDX

Apr 05, 2024 | Team Kalkine
One Health Care Equipment & Services Stock Trading Near Resistance Levels – IDX

IDX:ASX
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (AU$)

Integral Diagnostics Limited (ASX: IDX)

IDX is an Australian healthcare services company involved in delivering diagnostic image services to general practitioners, patients, medical specialists, and allied health professionals.

Recommendation Rationale – SELL at AUD 2.380

  • Profit Decline: Operating NPAT decreased by over 5% to AUD 7.40mn in 1HFY24 vs 1HFY23, due to continued price rises and increased interest rates.
  • Outlook: The company expects to invest between AUD 30.0mn and AUD 40.0mn in replacement and expansion capital expenditures in FY24. The firm intends to improve its trade performance in 2HFY24 and attain an operating profit margin that equals or exceeds the 20.2% margin recorded in 2HFY23.
  • Emerging Risks: Technology changes, fluctuations in foreign currency, current adverse macroeconomic conditions, key personnel, regulatory constraints, and the decline in cash reserves over the last three years is a concerning risk for the healthcare firm, etc.
  • Overvalued Multiples:  On forward 12-month forward basis, key valuation multiples (Price/Earning, and Price/Cash Flow,) are higher than the median of the Healthcare industry.

IDX Daily Chart

Considering that the stock has crossed its resistance 1 level, hence representing a profit booking opportunity. Given its current trading levels, recent rally in the share price, and risks associated, it is prudent to book profit at the current levels. Hence, a ‘Sell’ recommendation is given on the stock at the current market price of AUD 2.380, at 3:30 PM AEDT, as of 5 April 2024.

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and geopolitical issues prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is neither an indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 5 April 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.

Stop-loss: In general, it is a level to protect further losses in case of any unfavourable movement in the stock prices.


Disclaimer-

This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services. Please note past performance is neither an indicator nor a guarantee of future performance.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.